Literature DB >> 27344204

Long-term trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk factors in Norway.

Stein I Hallan1, Marius A Øvrehus2, Solfrid Romundstad3, Dena Rifkin4, Arnulf Langhammer5, Paul E Stevens6, Joachim H Ix4.   

Abstract

Surveillance of chronic kidney disease (CKD) prevalence over time and information on how changing risk factors influence this trend are needed to evaluate the effects of general practice and public health interventions. Because very few studies addressed this, we studied the total adult population of a demographically stable county representative of Norway using cross-sectional studies 10 years apart (Nord-Trøndelag Health Study (HUNT)2 and Nord-Trøndelag Health Study (HUNT)3, 65,237 and 50,586 participants, respectively). Thorough quality-control procedures and comparisons of methods over time excluded analytical drift, and multiple imputations of missing data combined with nonattendance weights contributed to unbiased estimates. CKD prevalence remained stable in Norway from 1995 through 1997 (11.3%) to 2006 through 2008 (11.1%). The association of survey period with CKD prevalence was modified by a strong decrease in blood pressure, more physical activity, and lower cholesterol levels. Without these improvements, a 2.8, 0.7, and 0.6 percentage points higher CKD prevalence could have been expected, respectively. In contrast, the prevalence of diabetes and obesity increased moderately, but the proportion of diabetic patients with CKD decreased significantly (from 33.4% to 28.6%). A CKD prevalence of 1 percentage point lower would have been expected without these changes. Thus, CKD prevalence remained stable in Norway for more than a decade in association with marked improvements in blood pressure, lipid levels, and physical activity and despite modest increases in diabetes and obesity.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic kidney disease; epidemiology; general population; prevalence; risk factors; trend

Mesh:

Substances:

Year:  2016        PMID: 27344204     DOI: 10.1016/j.kint.2016.04.012

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

Review 1.  Kidney disease and obesity: epidemiology, mechanisms and treatment.

Authors:  Niels Olsen Saraiva Câmara; Kunitoshi Iseki; Holly Kramer; Zhi-Hong Liu; Kumar Sharma
Journal:  Nat Rev Nephrol       Date:  2017-01-16       Impact factor: 28.314

Review 2.  Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.

Authors:  Wenshan Lv; Fan Fan; Yangang Wang; Ezekiel Gonzalez-Fernandez; Chen Wang; Lili Yang; George W Booz; Richard J Roman
Journal:  Physiol Genomics       Date:  2017-11-10       Impact factor: 3.107

Review 3.  Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets.

Authors:  Wenshan Lv; George W Booz; Yangang Wang; Fan Fan; Richard J Roman
Journal:  Eur J Pharmacol       Date:  2017-12-08       Impact factor: 4.432

4.  Mortality risk among screened subjects of the specific health check and guidance program in Japan 2008-2012.

Authors:  Kunitoshi Iseki; Koichi Asahi; Kunihiro Yamagata; Shouichi Fujimoto; Kazuhiko Tsuruya; Ichiei Narita; Tsuneo Konta; Masato Kasahara; Yugo Shibagaki; Hisako Yoshida; Toshiki Moriyama; Masahide Kondo; Chiho Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2017-03-03       Impact factor: 2.801

Review 5.  Epidemiology of chronic kidney disease: an update 2022.

Authors:  Csaba P Kovesdy
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

Review 6.  CKD: A Call for an Age-Adapted Definition.

Authors:  Pierre Delanaye; Kitty J Jager; Arend Bökenkamp; Anders Christensson; Laurence Dubourg; Bjørn Odvar Eriksen; François Gaillard; Giovanni Gambaro; Markus van der Giet; Richard J Glassock; Olafur S Indridason; Marco van Londen; Christophe Mariat; Toralf Melsom; Olivier Moranne; Gunnar Nordin; Runolfur Palsson; Hans Pottel; Andrew D Rule; Elke Schaeffner; Maarten W Taal; Christine White; Anders Grubb; Jan A J G van den Brand
Journal:  J Am Soc Nephrol       Date:  2019-09-10       Impact factor: 10.121

7.  Dipstick proteinuria and all-cause mortality among the general population.

Authors:  Kunitoshi Iseki; Tsuneo Konta; Koichi Asahi; Kunihiro Yamagata; Shouichi Fujimoto; Kazuhiko Tsuruya; Ichiei Narita; Masato Kasahara; Yugo Shibagaki; Toshiki Moriyama; Masahide Kondo; Chiho Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2018-06-05       Impact factor: 2.801

8.  NiaoDuQing granules relieve chronic kidney disease symptoms by decreasing renal fibrosis and anemia.

Authors:  Xu Wang; Suyun Yu; Qi Jia; Lichuan Chen; Jinqiu Zhong; Yanhong Pan; Peiliang Shen; Yin Shen; Siliang Wang; Zhonghong Wei; Yuzhu Cao; Yin Lu
Journal:  Oncotarget       Date:  2017-06-14

Review 9.  Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies.

Authors:  Wenshan Lv; George W Booz; Fan Fan; Yangang Wang; Richard J Roman
Journal:  Front Physiol       Date:  2018-02-16       Impact factor: 4.566

10.  Life Course Trajectories of Cardiovascular Risk Factors in Women With and Without Hypertensive Disorders in First Pregnancy: The HUNT Study in Norway.

Authors:  Eirin B Haug; Julie Horn; Amanda R Markovitz; Abigail Fraser; Lars J Vatten; Corrie Macdonald-Wallis; Kate Tilling; Pål R Romundstad; Janet W Rich-Edwards; Bjørn O Åsvold
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.